Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
about
Hypoxia-inducible factor 1-mediated characteristic features of cancer cells for tumor radioresistanceChoosing the right cell line for renal cell cancer researchNoncoding RNAs in Tumor Epithelial-to-Mesenchymal TransitionImproving the radiosensitivity of radioresistant and hypoxic glioblastoma.PLK1 blockade enhances therapeutic effects of radiation by inducing cell cycle arrest at the mitotic phase.Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistanceAberrant IDH3α expression promotes malignant tumor growth by inducing HIF-1-mediated metabolic reprogramming and angiogenesis.Blocking HIF-1α following radiotherapy to prolong and enhance the immune effects of radiotherapy: a hypothesis.BAY 87-2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenograftsA therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.Evaluation of anti-HIF and anti-angiogenic properties of honokiol for the treatment of ocular neovascular diseases.Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function.Radiation, inflammation, and immune responses in cancerHypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.PERK/eIF2α signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS.MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines.Involvement of decreased hypoxia-inducible factor 1 activity and resultant G1-S cell cycle transition in radioresistance of perinecrotic tumor cells.Strategies To Assess Hypoxic/HIF-1-Active Cancer Cells for the Development of Innovative Radiation Therapy.Radiation induces aerobic glycolysis through reactive oxygen species.HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs.Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine.Modulating the tumor microenvironment to increase radiation responsiveness.LY6E: a conductor of malignant tumor growth through modulation of the PTEN/PI3K/Akt/HIF-1 axis.Heparanase promotes radiation resistance of cervical cancer by upregulating hypoxia inducible factor 1.Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?Microenvironment and radiation therapyThe tumour microenvironment after radiotherapy: mechanisms of resistance and recurrenceInhibition of Notch and HIF enhances the antitumor effect of radiation in Notch expressing lung cancer.Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer.Prognostic value of HIF-1α expression during fractionated irradiation.Radiation protective effect of hypoxia-inducible factor-1α (HIF-1α) on human oral squamous cell carcinoma cell lines.Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment.
P2860
Q26779535-F5E995B4-CF66-4BD4-BD58-4E890931AFA3Q28073283-F37211E7-E106-4211-AD57-AA2A7633576DQ28080346-0BCEE300-23DA-42D5-8368-7271C1DFE6C6Q30452219-7BF7EEBF-D3AB-49FC-A3A4-7244420236ACQ30670722-C9EA9FCD-33D0-446A-899B-1A76E4868B9DQ33820264-DAC4646D-5E1E-4677-9C93-0E7EB064F748Q34455116-86B3D94F-74B7-49B2-BFB8-3F4422FAF964Q34481866-0C44669A-C18B-4E5C-A563-7DD17A3DA07BQ34672437-374C41F6-FD2A-4C66-AE67-E5B59913F4B4Q35163974-5DD7F30A-A9EF-416A-89F5-45D991DA4E41Q35448249-37716597-4069-4D5A-99E0-C676F2D43F78Q35916654-FE023B59-AC52-4300-84D3-D3DF55604A76Q35949504-11163DE2-ED79-4AB4-9F68-63C722550680Q36005646-2730DED2-859B-4EAC-BC32-CDE06AE65C3CQ36220497-6684FD50-FF3F-420C-9A61-6FF252AC1D26Q36353046-8290B7BA-658A-4A20-9F9C-557D317F802BQ36712792-1671ED67-0587-4568-9FC0-6DEFA20BE338Q36738067-2D23E517-A78D-49B5-A914-B9D87C25BB2CQ36780880-720335BA-4E36-4E9B-99A2-7824446E8205Q37137456-9EA5F8FE-7DBA-42E9-91EC-DBCB7CFC54BCQ37163558-F43043BB-77DB-49C8-A609-09372B4D5E34Q37507008-F75FE972-B9FA-43AA-AC46-84633D989DE8Q37562355-6B3CD150-C536-4EAE-99FB-FEA328C4A501Q37613364-CA4D8486-191A-4CFD-B12C-E187385233E6Q37662321-57ECDFF6-5589-4A16-8D9E-7B6D739D7650Q37679989-27C31E3A-079C-4B45-BCC7-52A6FE4D146DQ37730085-9C3238F4-A237-4AC5-BAD0-EB77D9DAD868Q38091084-5924D6C0-6385-4194-841D-763711B67613Q38536374-1ABED247-8B3B-4C78-AE52-44D323C28A30Q38750553-7FD829A5-163F-4676-9D50-28C85849261FQ38884727-8E3EFC97-80B8-4785-8739-24A85966B406Q38989346-A4215462-0D8E-47FA-A3C7-010D3106DE82Q39262531-A87E39E2-7222-45DC-BAC0-718CF6C24027Q39289681-86198BBD-ACCA-4895-9ED4-DD4592D50AF1Q47093662-DB19525B-A937-487B-85CF-CF44185A67DF
P2860
Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Treatment regimen determines w ...... e effect of radiation therapy.
@en
type
label
Treatment regimen determines w ...... e effect of radiation therapy.
@en
prefLabel
Treatment regimen determines w ...... e effect of radiation therapy.
@en
P2093
P2860
P356
P1476
Treatment regimen determines w ...... e effect of radiation therapy.
@en
P2093
A Morinibu
K Shinomiya
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604939
P407
P577
2009-02-17T00:00:00Z